>
Fa   |   Ar   |   En
   Preventing Or Attenuating Amphotericin B Nephrotoxicity With Dopamine Receptor Agonists: A Literature Review  
   
نویسنده Karimzadeh Iman ,Khalili Hossein ,Sagheb Mohammad Mahdi
منبع Trends In Pharmaceutical Sciences - 2015 - دوره : 1 - شماره : 3 - صفحه:129 -138
چکیده    Nephrotoxicity is generally considered as the most clinically significant and dose-limiting adverse reaction of amphotericin b. currently, only the clinical effectiveness of salt loading and administering lipid formulations of amphotericin b have been clearly demonstrated to prevent its nephrotoxicity. in this review, we collected the published data related to dopamine receptor agonists in preventing amphotericin b nephrotoxicity. a literature search was conducted by the relevant keywords like ‘‘amphotericin b”, “nephrotoxicity’’, and ‘‘dopamine’’ in databases such as scopus, medline, embase and isi web of knowledge. four relevant articles were considered. results of all the 3 experimental studies demonstrated that co-administration of dopamine (0.5-10 μg/kg/min) as continuous intravenous infusion, sk&f r- 105058, a prodrug of fenoldopam (10 mg/kg twice daily), orally or fenoldopam, a relatively selective dopamine receptor type 1 agonist, (0.5 or 1 μg/kg/min) as continuous intravenous infusion can at least significantly mitigate the decrease in creatinine clearance caused by amphotericin b. furthermore, fenoldopam and sk&f r-105058 can also protect against or delay amphotericin b-induced tubular damage. in contrast, the only clinical trial published until now found that simultaneous continuous intravenous infusion of low dose dopamine (3 μg/kg/min) had no beneficial effect on the incidence, severity and time onset of developing amphotericin b-induced nephrotoxicity in autologous bone marrow transplant and leukemia patients. considering the lack of beneficial effects in different settings such as acute kidney injury of any cause, negative results of the only clinical trial, and risk of significant adverse reactions, continuous intravenous infusion of low dose dopamine (1-3 μg/kg/min) or selective dopamine receptor type 1 agonists (e.g., fenoldopam) currently appears to have no promising clinical role in preventing or attenuating amphotericin b nephrotoxicity.
کلیدواژه Amphotericin B ,Nephrotoxicity ,Dopamine Receptor Agonists ,Prevention
آدرس Shiraz University Of Medical Sciences, School Of Pharmacy, Department Of Clinical Pharmacy, ایران, Tehran University Of Medical Sciences Tums, Faculty Of Pharmacy, Department Of Clinical Pharmacy, ایران, Shiraz University Of Medical Sciences, Nephrology-Urology Research Center, Department Of Internal Medicine, ایران
 
     
   
Authors
  
 
 

Copyright 2023
Islamic World Science Citation Center
All Rights Reserved